

# **National Pharmaceutical Regulatory Agency**

Ministry of Health Malaysia Lot 36, Jalan Profesor Diraja Ungku Aziz, 46200 Petaling Jaya,

IGN GMP INSPECTION APPLICATION FORM						
	For Official Use Only					
	Application No.					
	Date Received:					
	Date Completed:					
ŀ	R INFORMATION					

Se Tel. No.	335400	,					
Fax No. : 03-79573 Website : <u>http://w</u>				Date Completed:			
PART A APPLICANT / PR	ODUC	REGISTRATION H	IOLDER	INF	ORMATION		
Name of Applicant:							
Name of Product Registration Hol	der:						
Address:							
Company/Business Registration N	lumber:						
Contact Telephone:	Contact	Fax:	Email Ad	ldress	5:		
PART B FOREIGN MANU	FACTUI	RER INFORMATIO	V				
Name:							
Address:							
Country:		Previous Date of Inspection by NPRA (if any):					
GPS Coordinate: Latitud	de	Ni los (ii dily).			Longitude		
PART C PURPOSE OF AP	PI TCAT	TON (Please tick the app	oronriate h	nv)			
Product Registration (		Total (reade tiek the up)		· ·	nge of Site to Existin	a Manufa	cturer
Product Registration (New)  Change of Site to Existing Manufacturer  Others (Specify):							
	RODUC	CT INFORMATION (	Please tick	tne a	ppropriate box)		
Category of products to be inspected (choose only ONE)		Sterile	[		Non-sterile		
		Large Volume Liquid			Tablet		Cream/Ointment
		Small Volume Liquid	[		Capsule		Solution
Product Dosage Form		Liquid for external use	e [		Powder		Suspension
		Liquid for internal use			Granule		Suppository
		Other (Specify):					
		Penicillin or Cephalosporin Hormone		Hormone			
Type of Product:		Cytotoxic or Anti-Cancer preparation Steroid		Steroid			
		Biologic (e.g. vaccines, ble	ood products	s, biote	chnology products)*		None of the above
*For Biological product: (choose only ONE)		Drug Substance			Drug Product		
Is the facility manufacturing registered products for other Product Registration Holder (PRH)?		Yes (Annex IV has to completed)	be		No		

(Version March 2023) Page 1 of 5

PART E	LIST OF SUPPORTING DOCUMENTS (The following documents <u>MUST</u> be submitted together with this application)	Tick (√) if provided	For Official Use Only	
1.	Payment of Processing Fee RM5,000.00			
2.	A copy of Company/Business Registration Certificate (for Product Registration Holder)			
3.	List of Building/Workshop/Line/Unit and dosage forms manufactured in each Building/Workshop/Line/Unit to be inspected			
4.	Details of new products to be registered in Malaysia (Annex I)			
5.	Details of existing registered products of renewal of product registration (Annex II)			
6.	Details of existing registered products for change of manufacturing site (Annex III)			
7.	Details of product registration holder and their respective registered products (Annex IV)			
8.	Site Master File			
9.	Validation Master File			
10.	Proposed flight route, including connecting flights (if any)			
	Hotel quotation [Details required:			
	i) Hotel Name, ii) Hotel Rate Per Night			
11.	iii) Official Website,			
	iv) Distance between hotel and manufacturing facility			
	v) Accommodation during transit (if any)			
12.	Entry requirements to the destination country for Malaysian citizens			
12	Declaration letter from manufacturer stating that the premise is ready to be inspected at			
13.	any time			
14.	14. Valid GMP evidence (preferably GMP certificate/report issued by a PIC/S Participating Authority)			

If company is eligible for **GMP DESKTOP ASSESSMENT (GDA)** (refer GDA acceptance criteria as mentioned below), the **ADDITIONAL** following documents (15-22) **MUST** be submitted together with this application (*Soft copy*).

#### GDA acceptance criteria:

- Manufacturing sites inspected by NPRA previously with an acceptable GMP status for the same dosage form(s)
- Applicable for sterile and non-sterile facilities (excluding biopharmaceuticals)
- Application of NPRA/431/11 is submitted at least 1 year before the expiry of GMP status (3 years after the last inspection date) for 1<sup>st</sup> GDA application
- For 2<sup>nd</sup> GDA application, NPRA/431/11 is submitted at least 1 year before GMP validity extension from the 1<sup>st</sup> GDA approval.

15.	GMP evidence by National Pharmaceutical Regulatory Agency (NPRA) i.e. GMP certificate	
16.	Regulatory Inspection List (all on-site inspections conducted within the past three years)	
17.	Warning letter or equivalent regulatory action issued by any authority [If none, refer to (16)]	
18.	Declaration from manufacturer (on company letter head) for item 15	
19.	Product complaint and recall register for the past three years	
20.	Change Control, Deviation, Quality Risk Assessment (QRM) register for the past three years	
21.	List of products manufactured within the last 6 - 12 months for the relevant products	
22.	GDA Pre-assessment (Please refer to Annex V)	

## PART F APPLICANT DECLARATION

- 1. I am hereby authorised by the company to make this application. I undertake to pay the non-refundable processing fee of RM 5,000 upon application and inspection fee of RM 20,000 at least one month before the foreign inspection is conducted using a banker's cheque payable to **BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN.** 
  - [Note: Only complete application form with confirmed payment will be processed by NPRA]
- 2. I have read and understood the contents of the Drug Registration Guidance Document and Guidance Document Foreign GMP Inspection.
- I hereby declare that details furnished on this form are true, accurate and complete; the supporting documents are authentic or true copies and undertake to notify NPRA, in writing, within one week of any changes in the particulars submitted in this application.
- 4. I understand that the final decision on performing GDA is based on the acceptance criteria stated in Part E and screening process through GMP Desktop Assessment Selection Tools (GDAST).
- 5. I undertake to pay all required inspection expenses which include flight ticket, accommodation, and other associated expenses (such as allowances, insurance, etc.) if inspection is required by NPRA. I shall make the payment in the form of contribution into a trust fund established under the Malaysian Ministry of Health (MOH) namely Akaun Amanah Penilaian, Pengiktirafan Akreditasi dan Pemeriksaan APB (Main Code: 886341, Sub Code: 4001) through a banker's cheque made payable to:

Name : KETUA SETIAUSAHA KEMENTERIAN KESIHATAN MALAYSIA

Account No : 21401360003459

(Version March 2023) Page **2** of **5** 

- I undertake to add more contribution to the trust fund if the expenses for the inspection are more than expected. I understand 6. that in the event where the foreign inspection cannot be conducted, the contribution will be refunded.
- 7. I understand that the remainder of the contribution will be retained in the trust fund for future purposes as outlined in the Arahan Amanah Penilaian, Pengiktirafan Akreditasi dan Pemeriksaan APB.
- I hereby confirm that the foreign manufacturer has agreed and is ready to be inspected at any time by NPRA, Malaysia. 8.
- I undertake to ensure that the medicinal products are manufactured in accordance with the GMP guidelines as determined by 9. the NPRA.
- I confirm that the new products to be registered in Malaysia are licensed/certified for sale in the country of manufacture/product
- owner. 11. I have read and agree to the terms and conditions stated in the current Guidance Document Foreign GMP Inspection and accept the decision by NPRA regarding this application. (Signature) (Date) (Company Stamp)

(Name & Designation)

PART	ADDITIONAL DECLARATIO	ON (Only applicable if the facility is manufact	uning registered products for other PKH)
2. All the of	rmation stated in Annex IV is true,		ion may affect the registration status of all the
1)	(Signature) Name & Designation)	(Date)	(Company Stamp)

(Version March 2023) Page 3 of 5

ANNEX I (Details of new products to be registered in Malaysia)							
No.	Product Name (Reference No If any)	Active Ingredient		nt	Dosage Form		The product is licensed/certified for sale in the country of manufacture/product owner (Yes/No)
			ANI	NEX I	ī.		
		of existing reg	gistered produ	ıcts for ı	renewal of product re	egistration)	
No.	Product Name		Regist	tratio	n Number		Registration Period
	ANNEX III						
No			tration		change of manufact	Cur	rent Manufacturer Name &
No.	Product Name	Nui	mber	Reg	istration Period		Address
ANNEX IV  (Details of product registration holder and their respective registered products)							
No.	Product Registration I				duct Name		Registration Number

(Version March 2023) Page **4** of **5** 

	ANNEX V (GDA Pre-assessment)						
No.	GDA Parameters of Pre-assessment	Please (√) only one					
1.	Number of employees.	☐ more than 150 employees					
		☐ 50 – 150 employees					
		☐ less than 50 employees					
2.	The maximum number of different manufacturing/distribution	☐ More than 7 processes					
	process.	☐ 4 – 6 processes					
		☐ 1 – 3 processes					
3.	The level of dedication of equipment and facilities that is in	☐ No dedication					
	place at the site (for e.g.: No dedication, partial dedication,	☐ Partial dedication					
	full dedication).	☐ Full dedication					
4.	Involvement of Real Time Release Testing (RTRT)	☐ Real Time Release Testing (RTRT) activities					
		☐ No Real Time Release Testing (RTRT) activities					
5.	Complexity of products manufactured (for e.g.: low	☐ Complex product type (low concentration / high					
	concentration/high potency, sustained release, normal	potency, sustained release)					
	product, biological).	☐ Normal product					
		☐ Repacking only					
6.	The maximum number of unit operations in a non-sterile	☐ More than 6 processes					
	manufacturing process (e.g.: dispensing, mixing, granulate, drying, coating, blister, packing, testing, IPQC)	☐ 4 – 5 processes					
		☐ Less than 3 processes					
7.	Involvement of repackaging activities (for e.g.: primary,	$\square$ Packing of products for clinical trials, primary repack					
	secondary).	☐ Secondary repack					
		☐ No repack activities					
8.	Engagement of sub-contract activities (for e.g.: contract lab,	$\square$ Subcontracting of processes / stages of manufacturing,					
	transport). Can tick more than one	primary packaging and QC					
		☐ Subcontracting services: contract lab, transport etc.					
	The manifestory assumbly of commonwhales a constant in a constant in all of	□ No subcontracting					
9.	The maximum number of components in a product, include final pack (for e.g.: vial, diluent, syringe, leaflet).	☐ More than 4 components					
	mai pack (15) eight than anderly synnige, leaneth	2 – 3 components					
10	Any made at with an offic stands are viscous	1 component (primary packaging)					
10.	Any product with specific storage requirement.  Can tick more than one	Cold chain, shorter shelf life					
	Can der more than one	☐ Specified storage requirement					
		☐ No specific storage requirement					

(Version March 2023) Page **5** of **5** 

<sup>\*</sup>Please refer to Guidance Document for Foreign Inspection (Appendix 3) for the description of the parameters.